probenecid has been researched along with Pelvic Inflammatory Disease in 9 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Pelvic Inflammatory Disease: A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES; (SALPINGITIS); the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter randomized comparative trial was done to assess the safety and efficacy of oral ofloxacin (400 mg twice daily for 10 days) versus cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days) for the outpatient treatment of uncomplicated pelvic inflammatory disease (PID)." | 9.07 | Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. ( Berkeley, A; Binder, D; Faro, S; Gordon, S; Martens, MG; Yarborough, DR, 1993) |
| "To evaluate guidelines for outpatient treatment of acute pelvic inflammatory disease recommended by the Center for Disease Control we studied 197 afflicted women." | 5.26 | Evaluation of tetracycline or penicillin and ampicillin for treatment of acute pelvic inflammatory disease. ( Cunningham, FG; Gilstrap, LC; Hauth, JC; Herbert, WN; Kappus, SS; Strong, JD; Wilson, RH, 1977) |
| "A multicenter randomized comparative trial was done to assess the safety and efficacy of oral ofloxacin (400 mg twice daily for 10 days) versus cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days) for the outpatient treatment of uncomplicated pelvic inflammatory disease (PID)." | 5.07 | Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. ( Berkeley, A; Binder, D; Faro, S; Gordon, S; Martens, MG; Yarborough, DR, 1993) |
| "Recurrent pelvic inflammatory disease was associated with an almost 2-fold increase in infertility and more than 4-fold increase in CPP." | 2.76 | Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. ( Bass, D; Haggerty, C; Ness, RB; Trent, M, 2011) |
| "Women with mild-to-moderate pelvic inflammatory disease were assessed after treatment initiation at 5 days for tenderness (n = 713) and at 30 days for tenderness, cervical infections and endometritis (n = 298)." | 2.73 | Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? ( Bass, DC; Kip, KE; Nelson, DB; Ness, RB; Peipert, JF; Richter, HE; Schubeck, D; Soper, DE; Trautmann, GM; Trout, W, 2008) |
| "We evaluated the effect of treatment of gonorrhea on simultaneous Chlamydia trachomatis infection by randomly assigning 293 heterosexual men and 246 heterosexual women with gonorrhea to receive one of the following treatment regimens: (1) 4." | 2.65 | Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. ( Guinan, ME; Holmes, KK; Johnson, C; McCormack, WM; Stamm, WE; Starcher, T, 1984) |
| "To evaluate guidelines for outpatient treatment of acute pelvic inflammatory disease recommended by the Center for Disease Control we studied 197 afflicted women." | 1.26 | Evaluation of tetracycline or penicillin and ampicillin for treatment of acute pelvic inflammatory disease. ( Cunningham, FG; Gilstrap, LC; Hauth, JC; Herbert, WN; Kappus, SS; Strong, JD; Wilson, RH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trent, M | 1 |
| Bass, D | 1 |
| Ness, RB | 3 |
| Haggerty, C | 1 |
| Levenson, D | 1 |
| Haggerty, CL | 1 |
| Amortegui, A | 1 |
| Hendrix, SL | 1 |
| Hillier, SL | 1 |
| Holley, RL | 1 |
| Peipert, J | 1 |
| Randall, H | 1 |
| Sondheimer, SJ | 1 |
| Soper, DE | 2 |
| Sweet, RL | 1 |
| Trucco, G | 1 |
| Trautmann, GM | 1 |
| Kip, KE | 1 |
| Richter, HE | 1 |
| Peipert, JF | 1 |
| Nelson, DB | 1 |
| Trout, W | 1 |
| Schubeck, D | 1 |
| Bass, DC | 1 |
| Stamm, WE | 1 |
| Guinan, ME | 1 |
| Johnson, C | 1 |
| Starcher, T | 1 |
| Holmes, KK | 1 |
| McCormack, WM | 1 |
| Martens, MG | 1 |
| Gordon, S | 1 |
| Yarborough, DR | 1 |
| Faro, S | 1 |
| Binder, D | 1 |
| Berkeley, A | 1 |
| Henderson, RH | 1 |
| Cunningham, FG | 1 |
| Hauth, JC | 1 |
| Strong, JD | 1 |
| Herbert, WN | 1 |
| Gilstrap, LC | 1 |
| Wilson, RH | 1 |
| Kappus, SS | 1 |
| Barrett-Connor, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness Clinical Early of Transvaginal and Laparoscopic Approaches for Drainage of Tubo -Ovarian Abscess. Randomized Noninferiority[NCT03166982] | 80 participants (Anticipated) | Interventional | 2016-10-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for probenecid and Pelvic Inflammatory Disease
| Article | Year |
|---|---|
Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefoxitin; Chronic Pain; Doxycycline; Female; Follow-Up St | 2011 |
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Cefoxitin; Chla | 2003 |
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?
Topics: Administration, Oral; Adolescent; Adult; Cefoxitin; Dose-Response Relationship, Drug; Doxycycline; D | 2008 |
Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis.
Topics: Adolescent; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Female; Gonor | 1984 |
Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group.
Topics: Adolescent; Adult; Ambulatory Care; Cefoxitin; Chlamydia Infections; Chlamydia trachomatis; Doxycycl | 1993 |
4 other studies available for probenecid and Pelvic Inflammatory Disease
| Article | Year |
|---|---|
Outpatient pelvic inflammatory disease treatment as effective as inpatient care, study finds.
Topics: Ambulatory Care; Cefoxitin; Cost Savings; Doxycycline; Female; Hospitalization; Humans; Infertility; | 2002 |
Recommended treatment schedules for Gonorrhea--1974.
Topics: Ampicillin; Child; Female; Gonorrhea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Pelv | 1975 |
Evaluation of tetracycline or penicillin and ampicillin for treatment of acute pelvic inflammatory disease.
Topics: Acute Disease; Adult; Ampicillin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Inject | 1977 |
Gonorrhea.
Topics: Adolescent; Adult; Ampicillin; Diagnosis, Differential; Drug Therapy, Combination; Female; Gonorrhea | 1973 |